Tag Archives: metabolic syndrome

Impact of Abdominal Obesity on Incidence of Adverse Metabolic Effects Associated With Antihypertensive Medications — Cooper-DeHoff et al. 55 (1): 61 — Hypertension

Impact of Abdominal Obesity on Incidence of Adverse Metabolic Effects Associated With Antihypertensive Medications — Cooper-DeHoff et al. 55 (1): 61 — Hypertension

Impact of Abdominal Obesity on Incidence of Adverse Metabolic Effects Associated With Antihypertensive Medications
Rhonda M. Cooper-DeHoff; Sheron Wen; Amber L. Beitelshees; Issam Zineh; John G. Gums; Stephen T. Turner; Yan Gong; Karen Hall; Vishal Parekh; Arlene B. Chapman; Eric Boerwinkle; Julie A. Johnson

From the Colleges of Pharmacy (R.M.C.-D., S.W., J.G.G., Y.G., J.A.J.) and Medicine (R.M.C.-D., J.G.G., K.H., J.A.J.) and Center for Pharmacogenomics (R.M.C.-D., S.W., J.G.G., Y.G., J.A.J.), University of Florida, Gainesville, Fla; School of Medicine (A.L.B.), University of Maryland, Baltimore, Md; US Food and Drug Administration (I.Z.), Silver Spring, Md; Mayo Clinic College of Medicine (S.T.T.), Rochester, Minn; Morehouse School of Medicine (V.P.), Atlanta, Ga; School of Medicine (A.B.C.), Emory University, Atlanta, Ga; Human Genetics Center and Institute of Molecular Medicine (E.B.), University of Texas at Houston, Houston, Tex.

Correspondence to Rhonda M. Cooper-DeHoff, Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, 1600 SW Archer Rd, Box 100486, Gainesville, FL 32610-0486. E-mail [email protected]

We assessed adverse metabolic effects of atenolol and hydrochlorothiazide among hypertensive patients with and without abdominal obesity using data from a randomized, open-label study of hypertensive patients without evidence of cardiovascular disease or diabetes mellitus. Intervention included randomization to 25 mg of hydrochlorothiazide or 100 mg of atenolol monotherapy followed by their combination. Fasting glucose, insulin, triglycerides, high-density lipoprotein cholesterol, and uric acid levels were measured at baseline and after monotherapy and combination therapy. Outcomes included new occurrence of and predictors for new cases of glucose ≥100 mg/dL (impaired fasting glucose), triglyceride ≥150 mg/dL, high-density lipoprotein ≤40 mg/dL for men or ≤50 mg/dL for women, or new-onset diabetes mellitus according to the presence or absence of abdominal obesity. Abdominal obesity was present in 167 (58%) of 395 patients. Regardless of strategy, in those with abdominal obesity, 20% had impaired fasting glucose at baseline compared with 40% at the end of study (P<0.0001). Proportion with triglycerides ≥150 mg/dL increased from 33% at baseline to 46% at the end of study (P<0.01). New-onset diabetes mellitus occurred in 13 patients (6%) with and in 4 patients (2%) without abdominal obesity. Baseline levels of glucose, triglyceride, and high-density lipoprotein predicted adverse outcomes, and predictors for new-onset diabetes mellitus after monotherapy in those with abdominal obesity included hydrochlorothiazide strategy (odds ratio: 46.91 [95% CI: 2.55 to 862.40]), female sex (odds ratio: 31.37 [95% CI: 2.10 to 468.99]), and uric acid (odds ratio: 3.19 [95% CI: 1.35 to 7.52]). Development of adverse metabolic effect, including new-onset diabetes mellitus associated with short-term exposure to hydrochlorothiazide and atenolol was more common in those with abdominal obesity. Key Words: atenolol • hydrochlorothiazide • abdominal obesity • metabolic syndrome • new-onset diabetes mellitus • hypertension
Here’s the article…

Nuts and berries fight metabolic syndrome

Nuts and berries fight metabolic syndrome: “(NewsTarget) A number of recent studies have indicated that nuts and berries provide great advantages in averting metabolic syndrome, a cluster of symptoms linked to heightened risk of obesity, cardiovascular disease and diabetes.

Preliminary results from a Spanish study involving 9,000 people suggest that a Mediterranean diet leads to improved levels of cholesterol, blood glucose and blood pressure, all linked to metabolic syndrome. In particular, a Mediterranean diet supplemented with 15 grams of walnuts, 7.5 grams of hazelnuts and 7.5 grams of almonds per day appeared to provide a long-term 50 percent reduction in the risk of cardiovascular disease, more than the Mediterranean diet high in olive oil or the low fat diet. The research was published in the Archives of Internal Medicine.

In another study, researchers found that people who supplemented their everyday diet with 2-3 ounces of pistachios per day for four weeks showed significantly improved cholesterol ratios, perhaps due to their increased intake of fiber and lower intake of saturated fat. This study was published in the Journal of the American College of Nutrition.

‘This research challenges the previously held belief that a low-fat diet is best for heart health. Studies now show that a diet with a moderate amount of healthful monounsaturated fat, like the kind found in pistachios, is a more effective way to prevent heart disease than reducing overall fat intake,’ said lead researcher James Cooper.

In a long-term study of 34,000 post-menopausal women published in the American Journal of Clinical Nutrition, the consumption of flavonoid-rich foods such as berries was correlated with lowered incidence of cardiovascular disease over the course of 16 years.

An estimated 50 million people suffer from metabolic syndrome in the United States, placing them at a doubled risk of cardiovascular disease and five times the risk of diabetes compared with those who do not have the syndrome.”

(Via Nuts and berries fight metabolic syndrome.)